Abstract
A total of 590 strains of clinically important anaerobes were tested to determine their susceptibility to trovafloxacin. Overall, trovafloxacin had a mode MIC of 0.25 micrograms/ml and a MIC at which 90% of the isolates were inhibited of 1 micrograms/ml and had activity comparable to that of metronidazole. Trovafloxacin was 8-, 8-, 16-, 32-, and 64-fold more active than ampicillin-sulbactam, clindamycin, ciprofloxacin, cefoxitin, and cefotetan, respectively. Of the Bacteroides fragilis group, 97% of the isolates were inhibited by trovafloxacin at 21 micrograms/ml, and trovafloxacin was more active than ciprofloxacin, cefoxitin, cefotetan, ampicillin-sulbactam, and clindamycin against Clostridium, Fusobacterium, Porphyromonas, and Prevotella strains.
Full Text
The Full Text of this article is available as a PDF (203.3 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Aldridge K. E. Increased activity of a new chlorofluoroquinolone, BAY y 3118, compared with activities of ciprofloxacin, sparfloxacin, and other antimicrobial agents against anaerobic bacteria. Antimicrob Agents Chemother. 1994 Jul;38(7):1671–1674. doi: 10.1128/aac.38.7.1671. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Borobio M. V., Perea E. J. Effect of inoculum, pH, and medium on the activity of ciprofloxacin against anaerobic bacteria. Antimicrob Agents Chemother. 1984 Mar;25(3):342–343. doi: 10.1128/aac.25.3.342. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Child J., Andrews J., Boswell F., Brenwald N., Wise R. The in-vitro activity of CP 99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents. J Antimicrob Chemother. 1995 Jun;35(6):869–876. doi: 10.1093/jac/35.6.869. [DOI] [PubMed] [Google Scholar]
- Eliopoulos G. M., Klimm K., Eliopoulos C. T., Ferraro M. J., Moellering R. C., Jr In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrob Agents Chemother. 1993 Feb;37(2):366–370. doi: 10.1128/aac.37.2.366. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Girard A. E., Girard D., Gootz T. D., Faiella J. A., Cimochowski C. R. In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis. Antimicrob Agents Chemother. 1995 Oct;39(10):2210–2216. doi: 10.1128/aac.39.10.2210. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Goldstein E. J. Patterns of susceptibility to fluoroquinolones among anaerobic bacterial isolates in the United States. Clin Infect Dis. 1993 Jun;16 (Suppl 4):S377–S381. doi: 10.1093/clinids/16.supplement_4.s377. [DOI] [PubMed] [Google Scholar]
- Gooding B. B., Jones R. N. In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrob Agents Chemother. 1993 Feb;37(2):349–353. doi: 10.1128/aac.37.2.349. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Spangler S. K., Jacobs M. R., Appelbaum P. C. Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes. Antimicrob Agents Chemother. 1994 Oct;38(10):2471–2476. doi: 10.1128/aac.38.10.2471. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Teng R., Harris S. C., Nix D. E., Schentag J. J., Foulds G., Liston T. E. Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. J Antimicrob Chemother. 1995 Aug;36(2):385–394. doi: 10.1093/jac/36.2.385. [DOI] [PubMed] [Google Scholar]
- Wolfson J. S., Hooper D. C. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother. 1985 Oct;28(4):581–586. doi: 10.1128/aac.28.4.581. [DOI] [PMC free article] [PubMed] [Google Scholar]